[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynecological-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynecological-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,83,107,135,160,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100278638","ontario-wide-cancer-targeted-nucleic-acid-evaluation-100278638",false,"NCT02906943","Ontario-wide Cancer TArgeted Nucleic Acid Evaluation","OCTANE","Inclusion Criteria:\n\n1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.\n2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.\n3. Patient must be ≥ 18 years old.\n4. Patient's ECOG performance status equal to 0 or 1.\n5. All patients must have a life expectancy of \\> 6 months.\n6. All patients must have adequate organ functions.\n7. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent\u002Fmetastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.","ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.\n\nBiomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.\n\nThe study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.\n\nAnother goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.\n\nThe study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.",[24,25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Colorectal Cancer","Melanoma","Gynecological Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Cancer",[36,37,38,39,40],"Molecular Profiling","Advanced Cancer","Advanced Solid Tumors","Phase I Clinical Trial Candidates","Next Generation Sequencing","RECRUITING","2026-06-03",{"date":44,"type":45},"2026-06-05","ACTUAL",{"date":47,"type":4},"2016-08",{"date":49,"type":20},"2027-08",{"name":51,"class":52},"University Health Network, Toronto","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100519112","perioperative-immunonutrition-under-enhanced-recovery-after-surgery-100519112","NCT06039306","Perioperative Immunonutrition Under Enhanced Recovery After Surgery","Perioperative Immunonutrition Among Gynecological Cancer Patients Under Enhanced Recovery After Surgery","PING-ERAS","Inclusion Criteria:\n\n1. Those who diagnosed with GC\n2. Candidates for elective operation treatments\n\nExclusion Criteria:\n\n1. Those are involved gastrointestinal tract (complication)\n2. Those are diagnosed with GC (metastasis)\n3. Allergy to milk\u002Fsoy\u002Fwhey protein\n4. Participate in other intervention study","FEMALE","80 Years",{"count":64,"type":20},106,"INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to compare the effect of perioperative immunonutrition supplement in gynecologic cancer patients. The main questions it aims to answer are:\n\n* is there any difference in the nutritional outcomes and functional outcomes between intervention and conventional groups?\n* is there any difference in the post-surgical outcomes between intervention and conventional groups?\n\nParticipants (intervention) will be provided the immunonutrition supplement before and after operation.\n\nResearchers will compare intervention group with conventional group to see if there is any difference in postoperative outcomes.",[28,70],"Elective Surgery",[72],"gynecological cancer, elective surgery","2025-08-13",{"date":75,"type":45},"2025-08-19",{"date":77,"type":45},"2024-09-01",{"date":79,"type":20},"2025-10-30",{"name":81,"class":52},"Universiti Putra Malaysia",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":17,"maxAge":62,"enrollmentInfo":92,"targetDuration":4,"studyType":65,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":82},"100588968","evaluate-the-effectiveness-of-the-mobile-instant-messaging-intervention-100588968","NCT06948305","Evaluate the Effectiveness of the Mobile Instant Messaging Intervention","Exploring the Care Needs of Spouses of Gynecological Cancer Patients and Evaluating the Development of Care Plans","Inclusion Criteria:\n\n1. Age 18 or older, with a diagnosis of gynecological cancer (including cancers of the cervix, endometrium, fallopian tubes, ovaries, uterus, or vagina), and whose spouse has not been diagnosed with any other type of cancer;\n2. The spouse has undergone cancer treatment, including surgery, chemotherapy, or radiotherapy;\n3. Clear consciousness and ability to communicate in Mandarin or Taiwanese;\n4. Willingness to participate in the study after being informed of the study purpose and procedures.\n\nExclusion Criteria:\n\nIndividuals with psychiatric disorders.",true,"MALE",{"count":93,"type":20},70,[67],"This study explores the caregiving needs of male spouses and develops an instant messaging software intervention to provide effective support. The goal is to help male spouses better adjust to their caregiving roles, reduce psychological stress and emotional distress, and improve overall health.\n\nA randomized controlled trial will be conducted to evaluate the effectiveness of the mobile instant messaging intervention, analyzing its impact on reducing psychological distress and improving the quality of life of male spouses.",[28],"NOT_YET_RECRUITING","2025-04-28",{"date":100,"type":45},"2025-04-29",{"date":102,"type":20},"2025-08-01",{"date":104,"type":20},"2028-07-31",{"name":106,"class":52},"National Taipei University of Nursing and Health Sciences",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":82},"100342582","genomic-investigation-of-unusual-responders-100342582","NCT03740503","Genomic Investigation of Unusual Responders","GENIUS","Inclusion Criteria:\n\n1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.\n\n   1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months\n   2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)\n2. The patient must have sufficient archival tumor available for sequencing.\n3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:\n\n   a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.\n\n   b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program\n\n   Exclusion Criteria:\n   * None",{"count":115,"type":20},100,"Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and\u002For other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.",[118,24,119,26,29,28,120,121,122,33,123],"Cancer","Non-small Cell Lung Cancer","Upper Aerodigestive Tract Cancer","Pancreatobiliary Gastrointestinal Cancer","Melanoma (Skin)","Carcinoma of Unknown Primary",[118,24,125,26,29,28,120,121,126,33,34],"Non- small Cell Lung Cancer","Melanoma Cancer","2025-01-30",{"date":129,"type":45},"2025-01-31",{"date":131,"type":45},"2013-11-01",{"date":133,"type":20},"2025-11",{"name":51,"class":52},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":62,"enrollmentInfo":142,"targetDuration":4,"studyType":65,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":82},"100568057","laparoscopic-surgical-systems-for-gynecological-and-remote-surgical-treatment-100568057","NCT06676267","Laparoscopic Surgical Systems for Gynecological and Remote Surgical Treatment.","Exploratory Study on the Application of Laparoscopic Surgical Systems for Gynecological and Remote Surgical Treatment.","Inclusion Criteria:\n\n* Patients who require endoscopic surgery\n* Voluntarily participate in this study and sign informed consent in writing\n\nExclusion Criteria:\n\n* Patients with malignant tumors with clinical stage IV\n* Those who require emergency surgery\n* Presence of active bleeding, severe abnormal coagulopathy (prothrombin time (PT) or international normalized ratio (INR) greater than 1.5 times the upper limit of normal), or platelet count \\< 80×10\\^9\u002FL\n* Patient has severe cardiovascular or circulatory disease and cannot tolerate surgery\n* Participated in other clinical trials in the past 1 month\n* Inability to understand trial requirements, or inability to complete the study follow-up plan\n* Other conditions that are considered by the investigator to be inappropriate for enrollment",{"count":143,"type":20},5,[67],"Remote robot-assisted laparoscopic surgery will be performed for gynecological surgical treatment through 5G network, while the safety and effectiveness will be studied.",[28],[148,149,150],"Laparoscopic Surgical","gynecological","Telesurgery","2025-01-27",{"date":153,"type":45},"2025-01-28",{"date":155,"type":45},"2024-08-01",{"date":157,"type":20},"2026-10-31",{"name":159,"class":52},"Affiliated Hospital of Nantong University",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100577375","detection-of-circulating-therapeutic-monoclonal-antibodies-in-biological-samples-of-gynecological-cancer-patients-100577375","NCT06797479","Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.","IMMUNO_ASSAY","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of gynecological malignancy;\n* Patients currently undergoing or scheduled to undergo immunotherapy as part of their treatment regimen;\n* Age \\> 18 years;\n* Patients who are able and willing to provide written informed consent to participate in the study.\n* Availability of biological samples.\n\nExclusion Criteria:\n\n* Patients receiving concurrent treatment with other investigational drugs or therapies that may interfere with immunotherapy.\n* Presence of significant comorbidities or other medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results (e.g., severe autoimmune diseases, uncontrolled infections);\n* Pregnant or breastfeeding women;\n* Patients who have received prior monoclonal antibody therapy that could affect the study results;\n* Patients who are unable or unwilling to comply with the study procedures and follow-up requirements;\n* Brain metastases;\n* History of other malignancies within the last 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.",{"count":168,"type":20},12,"Quantification of anti PD-1 mAbs in cancer patients is extremely important to monitor pharmacokinetics and effectiveness of immunotherapy. To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical\u002Fanalytical assays.",[28,171],"Immunotherapy","2025-01-22",{"date":153,"type":45},{"date":175,"type":20},"2025-03-01",{"date":177,"type":20},"2030-12-01",{"name":179,"class":52},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":65,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":82},"100576094","supplemental-high-flow-oxygen-to-reduce-infections-in-obese-gynecological-cancer-patients-100576094","NCT06780813","Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients","Supplemental Administration of High Flow Oxygen to Enhance Postoperative Recovery and Reduce Infections in Obese Gynecological Cancer Patients","SAFE","Inclusion Criteria:\n\n* Obese (BMI\\>30kg\u002Fm2) gynecological cancer patients\n* Optimized preoperative CBC values (hemoglobin \\>11g\u002Fdl, WBC 4.000-11.000 X 109\u002FL, platelets 150,000 to 400,000 X 109\u002FL)\n* In the case of neoadjuvant therapy an interval longer than three weeks between the last cycle and the operation\n\nExclusion Criteria:\n\n* Active immunosuppresion\n* Preexisting infection of the abdominal wall\n* Preexisting sepsis","85 Years",{"count":190,"type":20},400,[67],"The incidence of surgical-site infection (SSI) and complications related to wound healing reaches 10-20% of gynecological cancer patients. Each complication may dramatically prolong the hospitalization period and increase the economic burden of hospital care. Appropriate wound care and tissue oxygenation are of special importance for wound healing. Assuming adequate perfusion, the easiest, safest, and most effective way to improve tissue oxygenation is to increase the fraction of inspired oxygen. However, there is considerable controversy as to whether supplemental oxygen actually reduces SSI and healing-related complications as to date, there is absence of relevant data.",[194,28,195],"Supplemental Oxygen","Surgical Site Infections",[197,198,199],"Supplemental oxygen","Surgical site infections","Gynecological cancer","2025-01-15",{"date":202,"type":45},"2025-01-17",{"date":204,"type":45},"2025-01-10",{"date":206,"type":20},"2026-05-01",{"name":208,"class":52},"National and Kapodistrian University of Athens"]